Clinical data | |
---|---|
Trade names | Gilotrif, Giotrif, Afanix |
Other names | BIBW 2992 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a613044 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 95% |
Metabolism | CYP not involved |
Elimination half-life | 37 hours |
Excretion | Faeces (85%), urine (4%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.239.035 |
Chemical and physical data | |
Formula | C24H25ClFN5O3 |
Molar mass | 485.94 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC).[2][3][4] It belongs to the tyrosine kinase inhibitor family of medications.[5] It is taken by mouth.[5][1]
It is mainly used to treating cases of NSCLC that harbour mutations in the epidermal growth factor receptor (EGFR) gene.[6]
It is on the World Health Organization's List of Essential Medicines.[7]
Gilotrif FDA label
was invoked but never defined (see the help page).Spreitzer
was invoked but never defined (see the help page).Minkovsky
was invoked but never defined (see the help page).FDA
was invoked but never defined (see the help page).TGA
was invoked but never defined (see the help page).